References
- McLean E, Cogswell M, Egli I, et al. Worldwide prevalence of anaemia, who vitamin and mineral nutrition information system, 1993–2005. Public Health Nutr. 2009;12(4):444–454.
- World Health Organization. 2001. Iron deficiency anaemia: assessment, prevention, and control. A guide for programme managers. Geneva: World Health Organization.
- Begum S, Latunde-Dada GO. Anemia of inflammation with an emphasis on chronic kidney disease. Nutrients. 2019;11(10):2424.
- Li JH, Luo JF, Jiang Y, et al. Red blood cell lifespan shortening in patients with early-stage chronic kidney disease. Kidney Blood Press Res. 2019;44(5):1158–1165.
- Nemeth E, Ganz T. Anemia of inflammation. Hematol Oncol Clin North Am. 2014;28(4):671–681, vi.
- Astor BC, Coresh J, Heiss G, et al. Kidney function and anemia as risk factors for coronary heart disease and mortality: the Atherosclerosis Risk in Communities (ARIC) study. Am Heart J. 2006;151(2):492–500.
- Mozos I. Mechanisms linking red blood cell disorders and cardiovascular diseases. Biomed Res Int. 2015;2015:682054.
- Song Y, Tang L, Han J, et al. Uric acid provides protective role in red blood cells by antioxidant defense: a hypothetical analysis. Oxid Med Cell Longev. 2019;2019:3435174.
- Hamburger M, Baraf HS, Adamson TC, 3rd, et al. Recommendations for the diagnosis and management of gout and hyperuricemia 1. Postgrad Med. 2011;123(6 Suppl 1):3–36.
- Zhang S, Wang Y, Cheng J, et al. Hyperuricemia and cardiovascular disease. Curr Pharm Des. 2019;25(6):700–709.
- Shahin L, Patel KM, Heydari MK, et al. Hyperuricemia and cardiovascular risk. Cureus. 2021;13(5):e14855.
- Smith E, March L. Global prevalence of hyperuricemia: a systematic review of population-based epidemiological studies (abstract). Arthritis Rheumatol. 2015;67(suppl 10):2236.
- Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res. 2020;12(7):3167–3181.
- Roman YM. The Daniel K. Inouye College of Pharmacy Scripts: perspectives on the epidemiology of gout and hyperuricemia. Hawaii J Med Public Health. 2019;78(2):71–76.
- Park JS, Kang MJ, Song JS, et al. Trends of gout prevalence in South Korea based on medical utilization: a national health insurance service database (2002–2015). J Rheum Dis. 2020;27(3):174–181.
- Ok EJ, Kim K, Park SB. Association between serum uric acid and oxidative stress in Korean adults. Korean J Fam Med. 2018;39(5):295–299.
- Kimura Y, Tsukui D, Kono H. Uric acid in inflammation and the pathogenesis of atherosclerosis. IJMS. 2021;22(22):12394.
- Mohanty JG, Nagababu E, Rifkind JM. Red blood cell oxidative stress impairs oxygen delivery and induces red blood cell aging. Front Physiol. 2014;5:84.
- Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44(5):595–601.
- Hall JE. Renal dysfunction, rather than nonrenal vascular dysfunction, mediates Salt-Induced hypertension. Circulation. 2016;133(9):894–906.
- Eun Y, Han KD, Kim DH, et al. Association between anemia and hyperuricemia: results from the Korean National Health and Nutrition Examination Survey. Sci Rep. 2019;9(1):19067.
- Nam GE, Kim YH, Han K, et al. Obesity Fact Sheet in Korea, 2019: Prevalence of obesity and abdominal obesity from 2009 to 2018 and social factors. J Obes Metab Syndr. 2020;29(2):124–132.
- Taylor R. Insulin resistance and type 2 diabetes. Diabetes. 2012;61(4):778–779.
- Park J, Ryu SY, Han MA, et al. The association of vitamin D with estimated glomerular filtration rate and albuminuria: 5th Korean National Health and Nutritional Examination Survey 2011–2012. J Ren Nutr. 2016;26(6):360–366.
- Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015;386(9995):801–812.
- Vyssoulis G, Karpanou E, Kyvelou SM, et al. Ambulatory blood pressure profile in anemic hypertensive patients. Int J Cardiol. 2010;145(2):301–302.
- Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38(5):1101–1106.
- Sánchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol. 2008;295(4):F1134–1141.
- Dinh QN, Drummond GR, Sobey CG, et al. Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension. Biomed Res Int. 2014;2014:406960.
- Mikami T, Sorimachi M. Uric acid contributes greatly to hepatic antioxidant capacity besides protein. Physiol Res. 2017;66(6):1001–1007.
- Uduagbamen PK, Ogunkoya JO, AdebolaYusuf AO, et al. Hyperuricemia in hypertension and chronic kidney disease: risk factors, prevalence and clinical correlates: a descriptive comparative study. IJCM. 2021;12(09):386–401.
- Serné EH, de Jongh RT, Eringa EC, et al. Microvascular dysfunction: a potential pathophysiological role in the metabolic syndrome. Hypertension. 2007;50(1):204–211.
- Hamza E, Metzinger L, Metzinger-Le Meuth V. Uremic toxins affect erythropoiesis during the course of chronic kidney disease: a review. Cells. 2020;9(9):2039.
- Ritz E, Haxsen V. Diabetic nephropathy and anaemia. Eur J Clin Invest. 2005;35 Suppl 3(Suppl 3):66–74.
- Rejeb H, Ben Khelifa M, Ben Abdallah J, et al. The Effects of Ramadan-Fasting (RF) on Inflammatory and Hematological Indices of Stable Chronic Obstructive Pulmonary Disease (COPD) male patients: a pilot study. Am J Mens Health. 2018;12(6):2089–2103.
- Villa A, Rizzi N, Vegeto E, et al. Estrogen accelerates the resolution of inflammation in macrophagic cells. Sci Rep. 2015;5:15224.
- Yang Q, Jian J, Katz S, et al. 17β-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. Endocrinology. 2012;153(7):3170–3178.
- Brovold H, Lund T, Svistounov D, et al. Crystallized but not soluble uric acid elicits pro-inflammatory response in short-term whole blood cultures from healthy men. Sci Rep. 2019;9(1):10513.
- Kuwabara M, Kanbay M, Hisatome I. Uric acid and hypertension because of arterial stiffness. Hypertension. 2018;72(3):582–584.
- Crișan TO, Cleophas MC, Oosting M, et al. Soluble uric acid primes TLR-induced proinflammatory cytokine production by human primary cells via inhibition of IL-1Ra. Ann Rheum Dis. 2016;75(4):755–762.
- Shi Y. Caught red-handed: uric acid is an agent of inflammation. J Clin Invest. 2010;120(6):1809–1811.
- Pagani A, Nai A, Silvestri L, et al. Hepcidin and anemia: a tight relationship. Front Physiol. 2019;10:1294.
- Soliman AT, De Sanctis V, Yassin M, et al. Iron deficiency anemia and glucose metabolism. Acta Biomed. 2017;88(1):112–118.